[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Instituto Mexicano del Seguro Social\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":454},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,48,81,107,143,168,198,225,253,275,314,343,370,401,426],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100645068","phase-4-effectiveness-and-safety-of-darunavircobicistat-plus-lamivudine-compared-with-darunavircobicistat-plus-tenofovir-alafenamideemtricitabine-in-virologically-suppressed-people-living-with-hiv-at-24-and-48-weeks-of-follow-up-100645068",false,"NCT07678268","Effectiveness and Safety of Darunavir\u002FCobicistat Plus Lamivudine Compared With Darunavir\u002FCobicistat Plus Tenofovir Alafenamide\u002FEmtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up","TLALOC-2","Inclusion Criteria:\n\n* Virologically suppressed men living with HIV, transitioning from a DRV\u002Fc (800 mg\u002F150 mg) + TDF\u002FFTC (300 mg\u002F200 mg) regimen for at least 48 weeks prior to the study\n* Viral suppression for 48 weeks prior to the study\n* Agree to participate in the study by signing a written informed consent form\n* Age ≥18 years\n* Glomerular filtration rate (GFR) by CDK-EPI ≥60 mL\u002Fmin\n* Beneficiaries of the Mexican Social Security Institute (IMSS) treated at the Infectious Diseases Hospital of the \"La Raza\" National Medical Center\n\nExclusion Criteria:\n\n* Withdrawal of informed consent\n* Loss of coverage\n* Failure to attend sample collection within the required timeframe","MALE","18 Years",{"count":19,"type":20},78,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","A single-center, open-label, randomized pilot clinical trial between March 2025 and March 2026 at the Hospital de Infectología \"La Raza\" National Medical Center in Mexico City. Eligible participants were adult males (≥18 years) with HIV-1 infection who had maintained virological suppression (HIV-1 RNA \\\u003C50 copies\u002FmL) for 48 weeks on either DRV\u002Fc + 3TC or DRV\u002Fc + TDF\u002FFTC prior to enrollment (TLALOC-1 trial), and had an estimated glomerular filtration rate (eGFR) by CKD-EPI ≥60 mL\u002Fmin\u002F1.73 m². The primary endpoints were virological efficacy and safety at 24 weeks.",[26,27,28],"HIV Infection","Antiretroviral Therapy","Lentivirus Infections",[30,31,32,33,34],"HIV infection","antiretroviral therapy","two drugs regimen","renal safety","neuropsychiatric adverse events","RECRUITING","2026-06-25",{"date":38,"type":39},"2026-07-01","ACTUAL",{"date":41,"type":39},"2025-07-10",{"date":43,"type":20},"2026-12-10",{"name":45,"class":46},"Instituto Mexicano del Seguro Social","OTHER_GOV",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":47},"100643864","the-effects-usability-satisfaction-barriers-and-benefits-of-a-remote-multidomain-website-based-intervention-to-prevent-cognitive-decline-in-older-adults-100643864","NCT07668440","The Effects, Usability, Satisfaction, Barriers, and Benefits of a Remote, Multidomain Website-based Intervention to Prevent Cognitive Decline in Older Adults","Preliminary Assessment of the Effects, Usability, Satisfaction, Barriers, and Benefits of a Remote, Multidomain Intervention Supported by a Website to Prevent Cognitive Decline in Older Adults","MeMoHealthCogR","Inclusion Criteria:\n\n* With and without cognitive complaints (i.e., they have responded 'yes' to the question: 'Do you feel that your memory or learning abilities have worsened recently?\").\n* They demonstrate independence in activities of daily living and instrumental activities of daily living. • With one or more vascular risk factors (for example, type 2 diabetes or hypertension).\n* With a score on the overall cognitive function test of≥ 24 on the Mini-Mental State Examination.\n* With a score between 0-4 on the Blessed Dementia Scale.\n* With a mobile phone or computer.\n* Have a companion, such as a child, spouse, or friend, who can support you during the assessment in case of an emergency.\n* Voluntary acceptance to participate in the study through a signed informed consent form prior to your participation.\n\nExclusion Criteria:\n\n* Depression (score \\> 15 according to the Epidemiological Studies Center Depression Scale - Revised \\[CESD-R\\]).\n* With a clinical diagnosis of any significant neurological or psychiatric disorder (for example, Parkinson's disease, schizophrenia).\n* With any heart disease.\n* Presence of a recent cancer diagnosis.\n* History of recent severe cardiovascular event (for example, myocardial infarction, stroke).\n* Significant orthopedic conditions (for example, severe osteoarthritis).\n* Uncontrolled blood pressure (very high \\> 180\u002F100 mmHg or very low \\\u003C 100\u002F60 mmHg).\n* Severe visual or hearing impairment.\n* Type 2 Diabetes Mellitus requires insulin to control hyperglycemia.","ALL","60 Years","75 Years",{"count":60,"type":20},71,[62],"NA","Mexico exhibits a high prevalence of dementia, exceeding 8%, and it is estimated that by 2050 around 3.5 million older adults will be living with this condition. In light of this scenario, it becomes a priority to intervene on the factors associated with the development of dementia through preventive strategies, particularly via multicomponent programs that integrate physical activity, cognitive training, and other components aimed at modifying lifestyles, applied early, before the appearance of clinical symptoms.\n\nIn order to expand access to this type of intervention for older adults with limited time or resources for face-to-face care, the implementation of preventive programs remotely through the use of digital media has been proposed. Web platforms constitute an accessible and cost-effective alternative for delivering complex interventions, such as the 'Mind and Movement for Cognitive Health (MeMo-Salud-Cog)' program, designed to promote lifestyles conducive to cognitive health and which has shown promising preliminary results in overall cognitive function, memory, executive function, and attention.\n\nHowever, the use of digital systems by older adults may be limited by barriers associated with ageing (cognitive, sensory, physical, and motivational), as well as social aspects (education and social isolation) or cultural factors (beliefs and perceived usefulness), which can affect the continuity of their participation. In this context, the present proposal suggests adapting the MeMo-Salud-Cog program to a remote modality, through a website and remote monitoring by healthcare professionals, with the aim of evaluating its feasibility based on usability, satisfaction, effect, and adherence, as well as analyzing perceived acceptability, emphasizng the barriers and benefits of remote intervention.\n\nThe investigators will employ a mixed design combining quantitative and qualitative methods, with a pre-post evaluation without a control group in the quantitative part and semi-structured interviews in the qualitative part (pilot study). The study population will consist of independent individuals aged 60 to 75 years affiliated with IMSS at the Family Medicine Unit 1 and 28, with or without cognitive complaints, but without impairment (MMSE ≥ 24), functional independence, at least one vascular risk factor, with a mobile phone or computer, and an informed consent letter.",[65],"Coginitive Dysfunction",[67,68,69,70,71,72],"Exercise","Cognitive Training","cognition","cognitive impairment","older adults","prevention","NOT_YET_RECRUITING","2026-06-19",{"date":36,"type":39},{"date":77,"type":20},"2026-07-06",{"date":79,"type":20},"2027-10-29",{"name":45,"class":46},{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":90,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":104,"leadSponsor":106,"locationsCount":47},"100644404","coronary-artery-calcium-score-in-hiv-mexican-population-the-cacshivmex-study-100644404","NCT07662161","Coronary Artery Calcium Score in HIV Mexican Population (The CACsHIVMex Study)","CACsHIVMex","Inclusion Criteria:\n\n* Patients who have been diagnosed with HIV infection for more than 6 months\n* Undetectable viral load\n\nExclusion Criteria:\n\n* Patients who have previously taken statins\n* Patients with chronic ischemic heart disease that has required stenting or revascularization",{"count":89,"type":20},384,"4 Years","OBSERVATIONAL","The risk of atherosclerotic cardiovascular disease is increased in people with HIV infection, including young patients and those with few traditional cardiovascular risk factors. The increased risk of cardiovascular disease among people living with HIV is due to accelerated atherosclerosis, caused by chronic inflammation and immune dysregulation. The measurement of coronary calcium using plain computed tomography is a subclinical indicator of coronary atherosclerosis and is associated with the risk of cardiovascular events and mortality in the general population.",[94],"HIV - Human Immunodeficiency Virus",[96,97,98,99],"coronary calcium","coronary calcification","cardiovascular risk","major adverse cardiovascular events","2026-06-18",{"date":102,"type":39},"2026-06-23",{"date":38,"type":20},{"date":105,"type":20},"2030-07",{"name":45,"class":46},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":116,"minAge":17,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":121,"conditions":122,"keywords":127,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":47},"100637669","effect-of-a-self-efficacy-based-educational-intervention-on-breastfeending-in-primigravid-women-a-randomized-controlled-trial-100637669","NCT07593716","Effect of a Self-Efficacy-Based Educational Intervention on Breastfeending in Primigravid Women: A Randomized Controlled Trial","Effect of a Self-Efficacy-Based Educational Intervention on Exclusive Breastfeeding in Primigravid Women Attending a Primary Care Center: A Randomized Controlled Trial","PROMILACT","Inclusion Criteria:\n\n* Pregnant women aged 18 years or older\n* Primigravidae in the third trimester of pregnancy\n* Receiving prenatal care at UMF No. 9, IMSS\n* Ability to attend the educational sessions\n* Willingness to participate and sign informed consent\n\nExclusion Criteria:\n\n* High-risk pregnancy\n* Medical conditions contraindicating breastfeeding\n* Cognitive impairment or communication difficulties preventing participation\n* Previous participation in breastfeeding educational programs\n* Failure to complete follow-up evaluations",true,"FEMALE","45 Years",{"count":119,"type":20},160,[62],"This randomized controlled trial aims to evaluate the effect of a self-efficacy-based educational intervention on exclusive breastfeeding among primigravid women attending a primary care center in Mexico. Participants in the intervention group will receive four weekly educational sessions focused on breastfeeding knowledge, self-efficacy, problem-solving skills, and emotional support during the third trimester of pregnancy. The control group will receive standard prenatal care. Breastfeeding self-efficacy and exclusive breastfeeding rates will be evaluated during postpartum follow-up at 1 and 3 months after delivery.",[123,124,125,126],"Exclusive Breastfeeding","Breastfeeding Self-Efficacy","Pregnancy","Maternal Health Education",[128,129,130,131,132,133,134],"Breastfeeding","Primigravid Women","Educational Intervention","Randomized Controlled Trial","BSES-SF","Primary Care","Mexico","2026-05-12",{"date":137,"type":39},"2026-05-18",{"date":139,"type":20},"2026-05",{"date":141,"type":20},"2027-08",{"name":45,"class":46},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":4},"100634155","effectiveness-of-a-telerehabilitation-program-versus-a-conventional-rehabilitation-program-in-patients-with-subacromial-pain-100634155","NCT07536009","\"Effectiveness of a Telerehabilitation Program Versus a Conventional Rehabilitation Program in Patients With Subacromial Pain\"","Inclusion Criteria:\n\n* Men and women aged 18 years or older.\n* Diagnosis of Subacromial Impingement Syndrome (SIS) based on clinical criteria (pain with overhead activities, painful arc, positive Neer, Hawkins, or Jobe test). Radiological confirmation (ultrasound and\u002For magnetic resonance imaging) is accepted.\n* Access to the internet and a device (smartphone, tablet, or computer) capable of running the telerehabilitation platform.\n* Willingness and ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Shoulder pain caused by fractures, tumors, infections, or severe systemic pathologies.\n* Previous surgery on the affected shoulder within the last 3 months.\n* Prior joint injection (corticosteroid infiltration) in the affected shoulder within the last 3 months.\n* Subjects with partial or full-thickness rotator cuff tears.\n* Patients currently receiving concurrent physical therapy (PT) or any other external interventions for the shoulder condition.\n* Current participation in another rehabilitation or exercise program.\n* Pregnancy.\n* Cognitive impairment, communication barriers, or any condition that prevents the patient from following the remote instructions.",{"count":150,"type":20},82,[62],"The purpose of this prospective, randomized, parallel-group, single-center, controlled non-inferiority clinical trial is to determine whether a telerehabilitation program is non-inferior to a conventional rehabilitation program in patients with subacromial pain. Subacromial pain is a prevalent musculoskeletal condition, and while therapeutic exercise is the cornerstone of conservative management, adherence to home programs is often low. Conversely, conventional in-person physical therapy presents logistical and economic barriers for patients. This study aims to evaluate if a well-designed telerehabilitation program, utilizing information and communication technologies for remote monitoring, can provide an effective, accessible, and non-inferior alternative to conventional care. The primary outcome measured will be the change in shoulder function utilizing the QuickDASH questionnaire at 12 weeks. Secondary outcomes will assess pain intensity (VAS), range of motion (ROM), treatment adherence, and long-term functional outcomes.",[154],"Subacromial Impingement Syndrome",[156,157,154,158,159],"Telerehabilitation","Shoulder Pain","Exercise Therapy","Physical Therapy Modalities","2026-04-16",{"date":162,"type":39},"2026-04-21",{"date":164,"type":20},"2026-04-15",{"date":166,"type":20},"2027-05-30",{"name":45,"class":46},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":21,"phases":178,"briefSummary":179,"conditions":180,"keywords":183,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":47},"100592984","indocyanine-green-fluorescence-angiography-icg-fa-in-revisional-bariatric-surgery-100592984","NCT07000539","Indocyanine Green Fluorescence Angiography (ICG-FA) in Revisional Bariatric Surgery","Prospective Single-center Diagnostic Parallel-group Study to Determine the Minimal Dose of Indocyanine Green to Observe Vascular Perfussion in Revisional Bariatric Surgery.","BariGreen","Inclusion Criteria:\n\n* Diagnosis of obesity with a BMI ≥ 30 kg\u002Fm²\n* Scheduled for revisional bariatric surgery\n\nExclusion Criteria:\n\n* Allergy to iodides.\n* Anticoagulation with products containing sodium bisulfite (due to the risk of ICG-FA inactivation).\n* Use of radioactive iodine studies within the past 7 days.\n* Pregnant, breastfeeding, or planning to become pregnant within the next year (due to unknown teratogenic or fertility effects of ICG-FA).\n* History of liver disease or laboratory findings suggestive of moderate to severe hepatic disease: total bilirubin \\>1.5 times the upper limit of normal (ULN), or any elevation of aspartate aminotransferase (AST) above ULN.\n* Participants who withdraw their consent to participate in the study (elimination criterion).",{"count":177,"type":20},108,[62],"This study will compare different doses of a green fluorescent product that is administered during weight loss surgery in order to observe where blood vessels are located. There is uncertainty around the optimal dose of this product for patients with obesity, so this study will aim to study if the dose in the minimal range recommended by international guidelines is sufficient for most patients or if higher doses are needed with increasing body mass index.",[181,182],"Obesity","Bariatric Surgery",[184,185,186,187,188,189],"bariatric surgery","indocyanine green","vascular","weight loss surgery","Intraoperative Complications","Postoperative Complications","2026-03-23",{"date":192,"type":39},"2026-03-27",{"date":194,"type":39},"2025-05-06",{"date":196,"type":20},"2026-12-31",{"name":45,"class":46},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":21,"phases":208,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":47},"100624233","phase-2-safety-of-transmucosal-capsaicin-sphenopalatine-ganglion-stimulation-in-acute-ischemic-stroke-100624233","NCT07406971","Safety of Transmucosal Capsaicin Sphenopalatine Ganglion Stimulation in Acute Ischemic Stroke","Safety of Transmucosal Capsaicin for Chemical Sphenopalatine Ganglion Stimulation in Acute Ischemic Stroke Within 24 Hours of Symptom Onset: A Randomized Double-Blind Placebo-Controlled Trial","Cap-SPGAS","Inclusion Criteria:\n\n* Age between 18 and 80 years.\n* National Institutes of Health Stroke Scale (NIHSS) score between 6 and 20 at screening.\n* Symptom onset within 24 hours prior to study intervention.\n* Pre-stroke modified Rankin Scale (mRS) score ≤1.\n* Provision of written informed consent by the participant or legally authorized representative.\n\nExclusion Criteria:\n\n* Intracranial hemorrhage on neuroimaging.\n* Severe impairment of consciousness judged by the investigator to preclude safe participation.\n* Persistent blood pressure \\>220\u002F120 mmHg after initial medical management.\n* Severe systemic disease that, in the investigator's judgment, may interfere with study participation or safety.",{"count":207,"type":20},46,[209],"PHASE2","This study will evaluate the safety and tolerability of a dissolvable oral film containing a very small dose of capsaicin (the compound that produces the \"hot\" sensation in chili peppers) in adults with acute ischemic stroke. The film is designed to stimulate nerves in the mouth that may activate the sphenopalatine ganglion, a structure involved in regulating blood flow to the brain. The main purpose of this study is to determine whether the capsaicin film can be given safely to patients with acute ischemic stroke when started within 24 hours of symptom onset.\n\nParticipants will be randomly assigned (like flipping a coin) to receive either the capsaicin oral film or a placebo film that looks and tastes similar but contains no capsaicin. Neither the participants nor the clinical team will know which film is given (double-blind). All participants will continue to receive standard medical care for acute ischemic stroke.\n\nAfter administration of the study film, participants will be closely monitored for side effects and changes in vital signs (blood pressure, heart rate, respiratory rate, temperature, and oxygen saturation) at prespecified time points up to 72 hours. The primary outcome is the frequency of adverse events related to the study product within 72 hours after treatment begins. Participants will also be followed clinically up to 3 months as part of usual stroke care.\n\nThe results of this study will help determine whether this approach is safe and feasible, and whether further studies are warranted.",[212],"Ischemic Stroke",[214,215,216],"Acute ischemic stroke","Capsaicin","Sphenopalatine ganglion stimulation","2026-02-12",{"date":219,"type":39},"2026-02-17",{"date":221,"type":39},"2025-09-01",{"date":223,"type":20},"2026-10-31",{"name":45,"class":46},{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":21,"phases":235,"briefSummary":237,"conditions":238,"keywords":241,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":250,"leadSponsor":252,"locationsCount":47},"100615821","phase-3-epicardial-cardiac-fat-ct-epic-ct-100615821","NCT07297589","Epicardial Cardiac Fat-CT (EPIC-CT)","Epicardial Cardiac Fat Comparative Trial","EPIC-CT","Inclusion Criteria:\n\n* Criteria for the fourth definition of acute myocardial infarction with and without ST-segment elevation.\n\n  * Diagnosed with type 2 diabetes.\n  * Initial serum high-sensitivity CRP value \\> 2.0 mg\u002FL.\n  * Clinically obese.\n  * LVEF \\>50%.\n\nExclusion Criteria:\n\n* Patients who have recently received immunosuppressive therapy\n* Patients with a history of ischemic heart disease\n* Known allergy to any of the medications used\n* Use of any of the study drugs more than 6 months prior to randomization\n* Patients experiencing diabetic ketoacidosis\n* Patients with hemodynamic instability (mean arterial pressure \\\u003C60 mmHg while on vasopressors)\n* Pregnant women\n* Patients with a history or current diagnosis of cancer\n* Patients with documented active infections, such as pneumonia or urinary tract infections\n* Patients with pancreatitis",{"count":234,"type":20},136,[236],"PHASE3","Both globally and nationally, heart disease remains the leading cause of death overall and across genders, with ischemic heart disease being the primary cause. It is now understood that multiple risk factors contribute to the development of this condition, notably type 2 diabetes mellitus and obesity, especially an increase in visceral fat. Among these, the role of epicardial fat volume in the presence of atheromatous plaques in patients with coronary artery disease has been emphasized, along with the link between its volume and the risk of ischemic cardiovascular events. Consequently, recent decades have seen focused research on the potential of epicardial fat as a marker for major adverse cardiac events and on strategies to reduce its volume as a treatment goal for patients with risk factors.\n\nSelective sodium-glucose cotransporter 2 inhibitors are drugs that, beyond their antihyperglycemic effect, have demonstrated cardiovascular benefits through various mechanisms, including a reduction in epicardial fat. This was supported by a previous study conducted by our research group, although no statistically significant difference was found. On the other hand, GLP-1 agonists are effective drugs for weight control in patients with severe obesity. However, little research has been done on their effect on more localized fat, such as epicardial fat.",[239,240],"STEMI - ST Elevation Myocardial Infarction","Epicardial Fat",[242,243,244,245],"Epicardial fat","STEMI","Semaglutide","Dapagliflozin","2025-12-30",{"date":248,"type":39},"2026-01-02",{"date":246,"type":39},{"date":251,"type":20},"2027-03",{"name":45,"class":46},{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":21,"phases":263,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":272,"leadSponsor":274,"locationsCount":47},"100615639","phase-3-effect-of-glp-1-and-antidiabetic-sglt2-agents-for-myocardial-infarction-and-ultrasensitive-inflammatory-surveillance-galactus-trial-100615639","NCT07295223","Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)","GLP-1 and Antidiabetic SGLT2 Agents for Myocardial Infarction and Ultrasensitive Inflammatory Surveillance: An Open-Label Pilot Study","GALACTUS","Inclusion Criteria:\n\n* Criteria for the fourth definition of acute myocardial infarction with ST-segment elevation.\n* Diagnosed with type 2 diabetes.\n* Initial serum high-sensitivity CRP value \\> 2.0 mg\u002FL.\n* Clinically obese.\n* LVEF \\>50%.\n\nExclusion Criteria:\n\n* Patients who have recently received immunosuppressive therapy\n* Patients with a history of ischemic heart disease\n* Known allergy to any of the medications used\n* Use of any of the study drugs more than 6 months prior to randomization\n* Patients experiencing diabetic ketoacidosis\n* Patients with hemodynamic instability (mean arterial pressure \\\u003C60 mmHg while on vasopressors)\n* Pregnant women\n* Patients with a history or current diagnosis of cancer\n* Patients with documented active infections, such as pneumonia or urinary tract infections\n* Patients with pancreatitis",{"count":262,"type":20},44,[236],"The primary risk factor for coronary artery disease is atherosclerosis, with inflammation playing a crucial role in the development and progression of this condition. It has now been proven that inflammation is key in the development of complications after an acute myocardial infarction. These complications can be immediate and mechanical, such as ventricular wall rupture and ventricular arrhythmia, or long-term, presenting as major cardiovascular events like heart failure.\n\nDuring acute myocardial infarction (AMI), circulating high-sensitivity CRP levels increase approximately 6 hours after the onset of ischemia. CRP levels measured between 24 and 72 hours after symptom onset are a significant prognostic marker for one-year outcomes. Higher high-sensitivity CRP levels at the time of AMI are linked to more severe coronary atherosclerotic lesions seen on angiography and lower LVEF one month after the event. A serum high-sensitivity CRP concentration greater than 10 mg\u002FL after an AMI indicates inflammation, reflecting myocardial necrosis, plaque rupture, and acute thrombosis. In patients with AMI, persistent or increasing CRP levels are strongly associated with a higher risk of all-cause and non-cardiovascular death, especially when inflammation (CRP \\> 2.0 mg\u002FL) continues for a year.\n\nAside from reperfusion therapy, very few pharmacological approaches have been used to reduce inflammation after AMI. One such approach was the use of colchicine in the COVERT-MI randomized, double-blind, multicenter trial. This trial compared five days of oral colchicine with a placebo and found no difference in infarct size between the groups at five days or three months, as measured by cardiac magnetic resonance imaging.\n\nSGLT-2 inhibitors are drugs that have revolutionized the management of cardiovascular diseases, offering proven benefits for patients with heart failure and notable nephroprotective effects. However, their use after acute myocardial infarction has not yet been sufficiently established, as the only two published clinical trials so far failed to meet their primary goal of reducing hospitalizations for heart failure. Additionally, evidence of their use in post-AMI inflammation exists only in experimental studies. In experimental studies, SGLT2 global-knockout (KO) mice were used to demonstrate that dapagliflozin significantly influences cardiac fibrosis and inflammation, and markedly alters the gene expression profiles of macrophages and fibroblasts. Moreover, dapagliflozin directly inhibited macrophage-mediated inflammation, thereby suppressing cardiac fibroblast activation.\n\nSimilarly, only experimental studies have shown that semaglutide decreases elevated levels of TNF-α, IL-6, ROS, and MDA in the serum and cardiac tissues of obese mice. By lowering the expression of Cxcl2, S100a8, and S100a9 in neutrophils, semaglutide may help reduce cardiac inflammation and oxidative stress.\n\nTherefore, the objective of this study is to compare the effects of dapagliflozin and semaglutide on inflammatory markers (hs-CRP and IL-6) in patients with acute ST-segment elevation myocardial infarction.",[266],"Acute Myocardial Infarction With ST Elevation",[243,244,245,268],"High-sensitivity PCR",{"date":270,"type":39},"2026-01-05",{"date":246,"type":39},{"date":273,"type":20},"2026-09",{"name":45,"class":46},{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":57,"enrollmentInfo":282,"targetDuration":4,"studyType":21,"phases":284,"briefSummary":285,"conditions":286,"keywords":294,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":313},"100598619","phase-4-effect-of-lidocaine-dexmedetomidine-on-pain-inflammation-and-oxidative-stress-after-bariatric-surgery-100598619","NCT07073846","Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery.","Efficacy of Lidocaine-Dexmedetomidine Combination Therapy in Reducing Post-Operative Pain, Inflammatory Response, and Oxidative Stress in Patients Undergoing Bariatric Surgery","Inclusion Criteria:\n\n* Adults aged 18 - 60 years\n* Male or female\n* Elective laparoscopic bariatric surgery\n* Post-operative pathway: post-anaesthesia care unit (PACU) followed by standard ward, with an expected in-hospital stay ≥ 24 h\n* ASA physical-status II or III\n\nExclusion Criteria:\n\n* Use of any loco-regional anaesthetic technique during the peri-operative period (transversus abdominis plane, paravertebral, spinal, epidural, erector spinae, or other abdominal wall blocks).\n* Current substance abuse or illicit drug use.\n* Previous abdominal surgery within the last 6 months.\n* Known hypersensitivity or allergy to lidocaine, dexmedetomidine, amide local anaesthetics, or α₂-adrenergic agonists.\n* Congestive heart failure, significant bradyarrhythmia, second- or third-degree atrio-ventricular block without pacemaker, severe hypotension, or current therapy with Class I\u002FIII anti-arrhythmic drugs.\n* Estimated glomerular filtration rate (eGFR) \\\u003C 60 mL min-¹ 1.73 m-² (moderate-to-severe renal impairment).\n* Severe hepatic impairment (Child-Pugh C).\n* Pregnancy or lactation.\n* Chronic opioid consumption \\> 30 mg oral morphine equivalents per day for \\> 4 weeks\n* Active seizure disorder, myasthenia gravis, or other neurologic disease contraindicating lidocaine infusion.\n* Patient cannot communicate\n* Patient does not want to fill in the questionnaire\n* Participation in another interventional study within the past 30 days.\n* Intra-operative conversion to open surgery.\n* Insufficient biological sample for biomarker analysis.\n* Premature discontinuation of the study drug during surgery for any reason that, in the judgement of the treating anaesthesiologist or investigators, prevents adequate exposure or assessment of safety variables (e.g., major haemorrhage \\> 200 mL, anaphylactic shock, failed intubation, inability to extubate, severe metabolic\u002Frespiratory acidosis, transfer to ICU while intubated).",{"count":283,"type":20},104,[23],"The goal of this randomized clinical trial is to find out whether giving an intravenous lidocaine + dexmedetomidine combination (LIDEX) during laparoscopic bariatric surgery can lower post-operative pain, inflammation, and oxidative stress in adults with obesity.\n\nThe main questions it aims to answer are:\n\n* Pain control: Does LIDEX reduce pain 24 hours after surgery, as measured with the International Pain Outcomes Questionnaire (IPOQ)?\n* Biomarkers: Does LIDEX lower blood levels of key inflammatory cytokines-interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-10 (IL-10)-and oxidative-stress markers-malondialdehyde (MDA), the reduced\u002Foxidized glutathione ratio (GSH\u002FGSSG), superoxide dismutase (SOD), and catalase-compared with the individual drugs or saline placebo?\n\nResearchers will compare four groups: lidocaine alone, dexmedetomidine alone, LIDEX, and placebo (saline solution, a look-alike substance that contains no drug) to learn which approach works best.\n\nParticipants will:\n\n* Receive an intravenous infusion of their assigned study drug(s) during surgery.\n* Provide three small blood samples (before surgery, immediately after, and three hours after).\n* Complete a short pain questionnaire (IPOQ) 24 hours after surgery.",[287,288,289,290,291,292,293],"Morbid Obesity Requiring Bariatric Surgery","Postoperative Pain","Postoperative Pain Management","Postoperative Analgesia","Postoperative Adjuvant Treatment","Postoperative Inflammatory Markers","Postoperative Inflammatory Response",[182,295,296,297,298,299,300,301,302,303,304],"Laparoscopic Sleeve Gastrectomy","Laparoscopic Gastric Bypass","Pain Management","Lidocaine-Dexmedetomidine","Multimodal Analgesia","Inflammatory Cytokines","Oxidative Stress","Opioid-sparing Anesthesia","Enhanced Recovery (ERAS)","Postoperarive Oxidative Stress","2025-11-26",{"date":307,"type":39},"2025-11-28",{"date":309,"type":39},"2025-10-06",{"date":311,"type":20},"2027-07-01",{"name":45,"class":46},2,{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":21,"phases":324,"briefSummary":325,"conditions":326,"keywords":329,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":47},"100595331","phase-4-safety-tolerability-and-effectiveness-of-dtg3tc-vs-bictafftc-in-pwh-without-antiretroviral-experience-100595331","NCT07031063","Safety, Tolerability and Effectiveness of DTG\u002F3TC vs BIC\u002FTAF\u002FFTC in PWH Without Antiretroviral Experience","Safety, Tolerability and Effectiveness of DOlutegravir\u002FLamivudine Compared With Bictegravir\u002FTenofovir Alafenamide\u002FEmtricitabine in People Living With HIV Without Antiretroviral Experience (TEOTL)","TEOTL","Inclusion Criteria:\n\n1. Men and women ≥18 years of age , diagnosed with HIV, and naive to antiretroviral treatment.\n2. HIV-1 RNA quantified by RT-PCR ≥500 and less than 500,000 copies\u002FmL.\n3. No history of PrEP or PEP use.\n4. Estimated glomerular filtration rate ≥30 mL\u002Fmin\u002F1.73 m2 SC.\n5. No current or planned use of medications associated with significant weight changes during the study period.\n6. Be a beneficiary of the Mexican Social Security Institute treated at the Infectious Diseases Hospital, La Raza National Medical Center.\n7. Willingness of the participant to give consent.\n\nExclusion Criteria:\n\n1. Diagnosis of metabolic syndrome.\n2. uncontrolled diabetes\n3. Contraindication to the use of INSTIs.\n4. Known mutations in any of the components of either regimen (second-generation INSTIs, 3TC\u002FFTC, or TAF).\n5. Co-medications that have potential interactions with any of the components of the antiretroviral regimens.\n6. Coinfection with hepatitis B or hepatitis C virus.\n7. High cardiovascular risk (Framinham \\>20% or AHA\u002FACC \\>7.5%).\n8. Use of recreational drugs with anorexigenic potential (crystal, methamphetamines, cocaine) 60 days prior to randomization.\n9. Hospitalization for acute or severe illness 30 days prior to randomization",{"count":323,"type":20},124,[23],"Background: The primary goal of antiretroviral therapy is to prevent HIV-associated morbidity and mortality. The effectiveness of first-line regimens is supported by a large number of clinical trials; current concerns focus on the long-term adverse effects of antiretrovirals, especially integrase strand transfer inhibitors, as they have been associated with significant weight gain, which may be associated with increased cardiovascular risk.\n\nObjective: To determine the effectiveness, safety, and tolerability of Dolutegravir\u002FLamivudine (DTG\u002F3TC) compared with Bictegravir\u002FTenofovir Alafenamide\u002FEmtricitabine (BIC\u002FTAF\u002FFTC) in treatment-naive people living with HIV (PWH). Materials and methods: With prior approval from the Ethics and Scientific Research Committee 3502, an open-label, randomized clinical trial will be conducted at the Infectious Diseases Hospital of the National Medical Center \"La Raza\" from November 2024 to May 2026. Recently diagnosed PWH with no history of PrEP and\u002For PeP use, without hospitalization criteria, and without a diagnosis of metabolic syndrome based on ATP-III criteria will be identified. They will be invited to participate in the study and, if they accept, they will sign an informed consent form. They will be randomized to start a BIC\u002FTAF\u002FFTC or DTG\u002F3TC 1:1 regimen. Laboratory studies, vital signs, and somatometry including bioimpedance will be performed at 4, 12, 24, 36, 48, 72, 96, 120, 144 weeks of follow-up; viral load and CD4+ count will be measured at weeks 12, 24, 48, 72, 96, 120, 144 weeks after the start of treatment. Sampling will be non-probabilistic; the distribution will be identified using the Kolmogorov-Smirnoff test, and measures of central tendency and percentages will be expressed. Comparisons will be made using the Mann-Whitney U test. Qualitative data will be analyzed using the x2 or Fisher's exact test. Group analysis will be performed at 12, 24, 48, 96 and 144 weeks using the Wilcoxon test. A P value ≤0.05 with a 95% confidence interval will be considered statistically significant.",[26,327,328],"Metabolic Syndrome","Antiretroviral Treatment",[330,331,332,333,334],"HIV","dual-therapy","BIC\u002FTAF\u002FFTC","DTG\u002F3TC","metabolic syndrome","2025-06-21",{"date":337,"type":39},"2025-06-26",{"date":339,"type":39},"2025-04-01",{"date":341,"type":20},"2028-12-01",{"name":45,"class":46},{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":21,"phases":353,"briefSummary":354,"conditions":355,"keywords":358,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":364,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":4},"100576644","phase-4-effect-of-dolutegravir-compared-with-darunavircobicistat-on-the-severity-of-neuropsychiatric-effects-al-12-weeks-in-antirretroviral-treatment-naive-adults-100576644","NCT06787976","Effect of Dolutegravir Compared With Darunavir\u002FCobicistat on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults.","Effect of Dolutegravir + Tenofovir Disoproxil Fumarato\u002FEmtricitabina Compared With Darunavir\u002FCobicistat + Tenofovir Disoproxil\u002FFumarato \u002FEmtricitabina on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults With HIV-1 Infection","MORFEO","Inclusion Criteria:\n\n* Patients living with HIV not experienced to ART\n* Age ≥ 18 years.\n* eGFR \\>60 mL\u002Fmin\n* Beneficiaries of the Mexican Social Security Institute treated at the \"La Raza\" National Medical Center\n* Patients with a baseline ISI scale score: ≥8-14 points\n* Patients with a baseline PHQ-9 scale score: 5-9 points\n* Patients with a baseline HADS-A scale score: 8-10 points\n* Patients with a baseline HADS-D scale score: 8-10 points\n* Patients with a baseline Pittsburgh scale score: 5-7 points.\n\nExclusion Criteria:\n\n* Patients with use of antidepressants\u002Fanxiolytics prior to starting ART\n* Any Contraindication for the use of second generation INSTI or IP ART regimen\n* Coinfection with Hepatitis C Virus\n* Known resistance mutations to any of the components of both treatment regimens.",{"count":352,"type":20},140,[23],"This clinical trial aimed at evaluating changes in neuropsychiatric scales for depression, anxiety, insomnia, and sleep quality in people living with HIV (PLHIV) who initiate antiretroviral therapy (ART) with a regimen of Dolutegravir (DTG) or Darunavir\u002FCobicistat (DRV\u002Fc), both combined with tenofovir disoproxil fumarate\u002Femtricitabine (TDF\u002FFTC).",[330,356,357],"Insomnia","Anxiety",[359,330,360,361,362,363,357],"INSTI","Dolutegravir","Darunavir","Suicide","Depression",{"date":337,"type":39},{"date":366,"type":20},"2025-06-19",{"date":368,"type":20},"2026-01-25",{"name":45,"class":46},{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":378,"enrollmentInfo":379,"targetDuration":4,"studyType":21,"phases":380,"briefSummary":381,"conditions":382,"keywords":388,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":313},"100562396","phase-4-change-in-body-weight-and-bmi-in-pwh-with-dor3tctdf-compared-with-insti-100562396","NCT06602622","Change in Body Weight and BMI in PWH with DOR\u002F3TC\u002FTDF Compared with INSTI","Change in Body Weight and BMI in PWH Virologically Suppressed Who Maintain a Second-generation INSTI Regimen Compared to Those Who Switch to DOR\u002F3TC\u002FTDF At 48 Weeks","TLATOANI","Inclusion Criteria:\n\n1. Virologically suppressed for at least 48 weeks prior to study entry\n2. Coming from a regimen containing Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide (BIC\u002FFTC\u002FTAF), Dolutegravir\u002FLamivudine\u002FAbacavir (DTG\u002F3TC\u002FABC), or, Dolutegravir\u002FTenofovir Disoproxil Fumarate\u002FEmtricitabine (DTG+TDF\u002FFTC) with no known failures to integrase inhibitors for al least 48 weeks.\n3. BMI ≥25 kg\u002Fm2 at screening and\n4. Unintentional weight gain of \\>10% from baseline (prior to INSTI initiation) within 1-3 years of starting INSTI ART, with no other apparent medical reason to explain the weight gain (concomitant medication use, Cushing's disease, recent prolonged hospitalization, etc.), in the opinion of the site investigator.\n5. Body fat percentage \\>20%\n6. No indication or plans to add or change medications associated with significant weight change during the study period.\n7. Participants currently receiving antipsychotics, antidepressants, anticonvulsants\u002Fmood stabilizers, and thyroid replacement hormones without dose modifications for at least 12 weeks prior to randomization\n8. Participants currently receiving antidiabetics known to cause weight loss and without dose modifications for at least 24 weeks prior to randomization (GLP-1 receptor agonists, SGLT-2 inhibitors, insulin, metformin).\n9. Agree to adhere to assigned ART during the study period\n10. HIV-1 RNA screening \\<50 copies\u002FmL performed within 45 days prior to study entry.\n11. GFR by CDK-EPI ≥60 mL\u002Fmin\n12. Alanine aminotransferase (ALT) and asparatate aminotransferase (AST) \\< 90 IU\u002FL\n13. Thyroid profile (TSH, free T3 and free T4) prior to entering the study\n14. Serum and urinary electrolytes, cystatin C, prior to entering the study\n\nExclusion Criteria:\n\n1. Loss of social security\n2. Allergy to any of the components of ART, previously unknown.\n3. Withdrawal of informed consent\n4. Acquiring HBV and\u002For HCV infection during follow-up.\n5. HIV-1 RNA \\>200 copies\u002FmL in 2 consecutive determinations after having achieved virological suppression.\n6. Early initiation or discontinuation of any of the following drugs after entering the study: antipsychotics (clozapine, olanzapine, risperidone); antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors) monoamine oxidase inhibitors, associated with weight gain; anticonvulsants\u002Fmood stabilizers (lithium, valproic acid) or associated with weight loss (topiramate); thyroid replacement hormones;\n7. Change in dose or discontinuation of antidiabetic drugs that cause weight loss (GLP-1 receptor agonists, SGLT-2 inhibitors, insulin, metformin), after entering the study.\n8. Planning to undergo or having undergone bariatric surgery.\n9. Initiating significant dietary changes, advised by a nutritionist according to what was reported by the participant\n10. Initiating or increasing physical exercise or enrolling in a structured weight loss regimen: \\<250 minutes\u002Fweek of moderate to intense activity","80 Years",{"count":177,"type":20},[23],"Patients who developed metabolic syndrome after initiation of HIV treatment or with antiretroviral therapy (ART) for at least 36 months, treated with second generation integrase inhibitors (BIC\u002FTAF\u002FFTC, DTG\u002FABC\u002F3Tc or DTG+TDF\u002FFTC) who have gained at least 10% of their total body weight after starting ART, with a body mass index ≥25 kg\u002Fm2 and body fat greater than 20% will be eligible to participate in this clinical trial. If they decide to participate, they will sign an informed consent. After this, a mobile application will randomly decide whether the participant will continue with their ART regimen or switch to another ART (listed in the guidelines as one of the main lines of treatment) containing doravirine\u002Flamivudine\u002Fdisoproxil fumarate tenofovir. Medical visits will be at 1 month, 3 months, 6 months, 9 months, and 12 months after get in to this protocol, with laboratory studies that evaluate fats, blood sugar, liver function, kidney function, and test for HIV control; in addition, each visit will be given self-fillable scales to evaluate neuropsychiatric disorders such as depression, anxiety, insomnia, satisfaction with treatment or symptoms associated with it.The aim of the study is to observe whether there is weight loss with the change in HIV treatment.",[330,383,384,385,386,387],"HIV Associate Weight Loss","HIV-1 Infection","Integrase Inhibitors, HIV; HIV PROTEASE INHIB","Weight Change","Weight Loss",[330,389,390,391,392],"Integrase inhibitors","doravirine","Body Mass Index","Body Weight Changes","2024-09-17",{"date":395,"type":39},"2024-09-19",{"date":397,"type":39},"2024-08-14",{"date":399,"type":20},"2025-11-14",{"name":45,"class":46},{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":21,"phases":410,"briefSummary":411,"conditions":412,"keywords":414,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":47},"100555772","parasternal-blockade-and-serum-lactate-in-cardiac-surgery-100555772","NCT06516432","Parasternal Blockade and Serum Lactate in Cardiac Surgery","Serum Lactate in the Application of Parasternal Blockade in Trans and Post Anesthetic Stages in Cardiac Surgery","Inclusion Criteria:\n\n* Adult patients older than 18 years\n* Either sex\n* ASA II-III\n* Patients who underwent cardiac surgery with median sternotomy and use of cardiopulmonary bypass.\n\nExclusion Criteria:\n\n* Patients with pre-existing conditions that could independently affect serum lactate levels.",{"count":409,"type":20},86,[62],"Serum lactate level is a key indicator of tissue perfusion. Parasternal blockade is associated with reduced postoperative inflammatory response by inhibiting stress response, leading to better outcomes. Elevated lactate levels help identify patients at risk of postoperative morbidity and mortality. This analytical cross-sectional study evaluated the association between parasternal blockade and serum lactate levels in patients undergoing elective cardiac surgery in 2022 at Specialty Hospital CMNO. Patients with and without parasternal block were compared for changes in serum lactate levels during and after anesthesia within the first 24 hours.",[413],"Elective Cardiac Surgery",[415,416,417],"Parasternal block","Cardiac surgery","Serum lactate","2024-07-18",{"date":420,"type":39},"2024-07-24",{"date":422,"type":39},"2024-01-01",{"date":424,"type":20},"2024-12-31",{"name":45,"class":46},{"id":427,"slug":428,"hasResults":11,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":11,"sex":56,"minAge":433,"maxAge":434,"enrollmentInfo":435,"targetDuration":4,"studyType":21,"phases":437,"briefSummary":438,"conditions":439,"keywords":443,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":47},"100553469","impact-of-a-playful-family-education-strategy-with-ict-on-childhood-obesity-prevention-100553469","NCT06486493","Impact of a Playful Family Education Strategy With ICT on Childhood Obesity Prevention","Effectiveness of a Family Playful \u002F Ludic Educational Strategy Reinforced With the Use of Information and Communication Technologies in the Prevention and Reduction of Childhood Obesity","Inclusion Criteria:\n\n* School-age children aged 9 to 12 years from the Family Medicine Unit Number 23 (IMSS, Mexico City) and the Family Medicine Units Number 1 and 3 (IMSS, Morelos).\n* Children accompanied by their parents who consent to participate in the study.\n* Children with a BMI equal to or greater than the 85th percentile (indicating overweight or obesity) according to CDC classification.\n* Children who have agreed to participate through informed consent and assent forms.\n* Families with access to Wi-Fi connection or mobile internet.\n* Children with digital device (Smartphone or Tablet) access, supervised by their parents.\n\nExclusion Criteria:\n\n* Children undergoing in any type of weight reduction program, whether pharmacological or non-pharmacological treatment .\n* Children with a prior diagnosis of endocrinological or congenital diseases, associated with obesity, such as hypothyroidism, Prader-Willi syndrome, growth hormone deficiency, Cushing's syndrome, trisomy 21, among others.\n* Children with abnormal thyroid function test results.\n* Children with physical limitations, such as congenital malformations, that may prevent them from engaging in moderate to intense physical activity included in the intervention.\n* Participants enrolled in another research protocol of any kind.","9 Years","12 Years",{"count":436,"type":20},196,[62],"The goal of this non-randomized clinical controlled trial is to evaluate the impact of a playful family education strategy reinforced by the use of communication technologies in childhood obesity. The main questions to answer are:\n\n* Does a technogical reinforced ludical family strategy might reduce overweight and childhood obesity prevalence and incidence reduction?\n* Can digital reinforcement might decrease body weight, BMI, body fat mass and waist circumference in overweight or obese children?\n* Does dietary habits might be improved by a technologically reinforced playful family workshop?\n\nResearchers will compare an obesity childhood digital reinforced group to an overweight control overweight group, an overweight workshop group and a childhood obesity control group to see if technological reinforcement works to reduce and prevent childhood obesity.",[440,441,442],"Pediatric Obesity","Childhood Obesity","Childhood Overweight",[440,441,444,445],"Educational Activities","Technology","2024-06-27",{"date":448,"type":39},"2024-07-03",{"date":450,"type":20},"2025-01",{"date":452,"type":20},"2029-12",{"name":45,"class":46},""]